LLLT to Reduce Low Back Pain
NCT06007976
Recruiting
The purpose of this research study is to gather information on the effectiveness of the Trident low-level laser therapy (LLLT) in combination with clinical patient education manuals to reduce lower back pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Low Back Pain
Register for Updates
IHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults with Type 1 Diabetes
NCT06348160
Recruiting
This research study aims to test a financial and health insurance iHERO Toolkit for young adults with type1 diabetes. The iHERO Toolkit was developed over one year with the type 1 diabetes community, The Diabetes Link organization, and experts. Now, the investigators want to understand the impact of the iHERO Toolkit on diabetes self-management, financial stress, and health insurance literacy outcomes. The investigators are doing this study because it will help to better understand how to suppor... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
03/14/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +3 locations
Conditions: Type 1 Diabetes
Register for Updates
BeCoMe-9: a Clinical Study of BE-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B
NCT06611436
Recruiting
The BeCoMe-9 Study (BE-101-01) is a Phase 1/2, first in human, multi-center, open-label, dose-escalation study to evaluate the safety and clinical activity of a single intravenous (IV) dose of BE-101 in adults with moderately severe or severe Hemophilia B. Once infused, BE-101 is designed to engraft and continuously secrete FIX into the circulation to restore clinically meaningful levels of active FIX. BE-101 is an autologous (person's own cells) B Cell Medicine (BCM) which uses CRISPR/Cas9 gene... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: University of Michigan, Ann Arbor, Michigan +2 locations
Conditions: Hemophilia B, Severe, Hemophilia B
Register for Updates
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06799000
Recruiting
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/14/2025
Locations: Johnson Dermatology, Fort Smith, Arkansas +5 locations
Conditions: Hidradenitis Suppurativa
Register for Updates
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
NCT01441089
Recruiting
Background: - Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: - To obtain a blood or cheek swab sample to study genetic differences that may affect cancer treatment. Eligibility: - Individuals with cancer who are being treated at the National Cancer Institute. De... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
03/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
Register for Updates
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
NCT03816319
Recruiting
This phase I trial studies the side effects and best dose of TAK-243 in treating patients with acute myeloid leukemia or myelodysplastic syndromes with increased blasts that has come back (relapsed) or that is not responding to treatment (refractory). TAK-243 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Moffitt Cancer Center, Tampa, Florida +2 locations
Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Register for Updates
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
NCT04562129
Recruiting
The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
Register for Updates
Association Between Body Composition and Pain in Spinal Cord Injury
NCT05459207
Recruiting
The purposes of the study are to quantify and compare relationships among acute changes in inflammatory markers and evoked pain sensitivity after a high-fat meal (HFM) challenge, compared to a moderate-fat meal challenge, and explore the influence of body composition on these responses, in individuals with chronic spinal cord injury
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/14/2025
Locations: University of Miami, Coral Gables, Florida
Conditions: Pain, Inflammatory Response
Register for Updates
Effect of Vagal Nerve Stimulation on Gastric Motor Functions
NCT06038929
Recruiting
The specific aim of this study is to compare simultaneous assessment of gastric emptying and gastric accommodation in response to the same caloric meal before and three months after activation of left cervical VNS. Our hypothesis is that cervical VNS increases gastric accommodation and accelerates gastric emptying.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: University of Minnesota, Minneapolis, Minnesota +1 locations
Conditions: Epilepsy, Depression
Register for Updates
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Research Site, Anchorage, Alaska +242 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Prospective Case Collection Study of Contrast-Enhanced Mammography Imaging Acquired on a New Investigational Device
NCT06636539
Recruiting
This is a prospective, single-center image case collection study to acquire de-identified contrast-enhanced breast images on the Investigational Device to support continuing technology development. Eligible subjects include women at least 35 years old with a suspicious finding or breast abnormality on a screening or diagnostic mammogram who are indicated for a diagnostic exam or a biopsy procedure.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
03/14/2025
Locations: Solis Mammography Memorial Village, Houston, Texas
Conditions: Breast Screening
Register for Updates
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
NCT06813781
Recruiting
This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, and severe hepatic impairment compared with participants with normal hepatic function.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/14/2025
Locations: Research Site, Lake Forest, California +3 locations
Conditions: Hepatic Impairment
Register for Updates